

# Francesca Bobbio-Pallavicini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7203859/publications.pdf>

Version: 2024-02-01

28  
papers

1,771  
citations

304602

22  
h-index

552653

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2256  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serious infections during anti-TNF $\alpha$ treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 266-273.	2.5	148
2	Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. <i>Arthritis Research</i> , 2004, 6, R264.	2.0	140
3	TNF $\alpha$ Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 837-846.	1.8	130
4	Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1021-1024.	0.5	114
5	High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor $\alpha$ inhibitors in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 302-307.	0.5	114
6	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 858-862.	0.5	112
7	Safety of tumor necrosis factor $\alpha$ blockers in hepatitis B virus occult carriers (hepatitis B surface) Tj ETQq1 1 0.784314 rgBT /Overloc <i>Research</i> , 2010, 62, 749-754.	1.5	110
8	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. <i>Autoimmunity Reviews</i> , 2009, 8, 274-280.	2.5	101
9	Safety and usefulness of minor salivary gland biopsy: Retrospective analysis of 502 procedures performed at a single center. <i>Arthritis and Rheumatism</i> , 2008, 59, 714-720.	6.7	100
10	Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. <i>Journal of Rheumatology</i> , 2007, 34, 1670-3.	1.0	94
11	Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 175-180.	2.5	80
12	DMARDS and infections in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2008, 8, 139-143.	2.5	70
13	Anti-cyclic citrullinated peptide antibodies in primary Sjogren's syndrome may be associated with non-erosive synovitis. <i>Arthritis Research and Therapy</i> , 2008, 10, R51.	1.6	64
14	Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 90-96.	2.9	63
15	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 431-437.	2.5	50
16	Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 465-469.	2.5	38
17	Long term treatment of rheumatoid arthritis with rituximab. <i>Autoimmunity Reviews</i> , 2009, 8, 591-594.	2.5	37
18	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 290.	1.6	37

#	ARTICLE	IF	CITATIONS
19	Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti-TNF $\hat{\pm}$ Treated Patients. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 287-295.	1.8	35
20	Anti-TNF $\hat{\pm}$ therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. <i>Autoimmunity Reviews</i> , 2009, 8, 260-265.	2.5	35
21	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. <i>PLoS ONE</i> , 2012, 7, e40362.	1.1	34
22	Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). <i>Reumatismo</i> , 2011, 60, 290-5.	0.4	29
23	Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 892-894.	0.5	17
24	What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?. <i>Journal of Rheumatology</i> , 2008, 35, 1903-5.	1.0	10
25	A proposal of simple calculation (ERI calculator) to predict the early response to TNF- $\hat{\pm}$ blockers therapy in rheumatoid arthritis. <i>Rheumatology International</i> , 2012, 32, 349-356.	1.5	7
26	Perivascular fibrosis and IgG4-related disease: a case report. <i>Reumatismo</i> , 2014, 66, 245-248.	0.4	2
27	Sp $\hat{\pm}$ cificit $\hat{\pm}$ 52 kDa et 60 kDa des anti-Ro(SS-A) dans les connectivites inclassables. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2000, 67, 197-202.	0.0	0
28	Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF- $\hat{\pm}$ blockade with etanercept. <i>International Urology and Nephrology</i> , 2011, 43, 909-912.	0.6	0